Evidence map›Paper›PMID 39584307›Full record

ArticleJournal of Alzheimer's disease : JAD2024

Exacerbated mitochondrial dynamic abnormalities without evident tau pathology in rapidly progressive Alzheimer's disease.

Yanbin Xiyang, Ju Gao, Mao Ding, Xiaojia Ren, Brian S Appleby, James B Leverenz, Masaru Miyagi, Jagan A Pillai, George Perry, Xinglong Wang

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Rock inhibitors in Alzheimer's disease.Frontiers in aging · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yanbin XiyangDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Ju GaoDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Mao DingDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Xiaojia RenDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.
Brian S ApplebyDepartments of Neurology, Pathology, and Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
James B LeverenzCleveland Clinic Neurological Institute, Lou Ruvo Center for Brain Health, Cleveland, OH, USA.
Masaru MiyagiDepartment of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Jagan A PillaiCleveland Clinic Neurological Institute, Lou Ruvo Center for Brain Health, Cleveland, OH, USA.
George PerryDepartment of Neuroscience, Developmental and Regenerative Biology, University of Texas at San Antonio, San Antonio, TX, USA.
Xinglong WangDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.ORCID 0000-0001-8657-0159

Funding

Translational and Therapeutics CoreP30AG072959 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Mark J Lowe · 2021 to 2026
$23.9M
Immune cell activation and associated blood brain barrier changes across different stages of Alzheimer's diseaseR01AG078763 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI JAGAN AYYAPPAN PILLAI · 2022 to 2026
$3.0M
FAM222A and amyloid plaque deposition in Alzheimer's DiseaseRF1AG066578 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI MIYAGI, MASARU, WANG, XINGLONG · 2020 to 2020
$2.8M
Mitochondrial modulation of neuroinflammation in AD and related tauopathiesRF1AG065342 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI WANG, XINGLONG · 2020 to 2020
$2.2M
Mitochondrial TDP-43 in Alzheimer's DiseaseRF1AG056320 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI WANG, XINGLONG · 2019 to 2019
$2.0M
FAM222A and amyloid plaque deposition in Alzheimer's DiseaseR01AG066578 · NIA · UNIVERSITY OF ARIZONA · PI WANG, XINGLONG · 2025 to 2025
$680k
Integrative analysis of proteomics and transcriptomics to delineate vesicular transport related protein abnormalities related to Alzheimer's, Lewy body and mixed PathologiesR21AG074287 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI BEBEK, GURKAN, PILLAI, JAGAN AYYAPPAN · 2022 to 2022
$456k
NIA NIH HHS P30 AG072959NIA NIH HHS R01 AG066578NIA NIH HHS R01 AG078763NIA NIH HHS R21 AG074287NIA NIH HHS RF1 AG056320NIA NIH HHS RF1 AG065342NIA NIH HHS RF1 AG066578
6 · The paper itself

Abstract

backgroundRapidly progressive Alzheimer's disease (rpAD) is a clinical subtype distinguished by its rapid cognitive decline and shorter disease duration. rpAD, like typical AD (tAD), is characterized by underlying neuropathology of amyloid plaques and neurofibrillary tangles. There is early evidence that the composition of amyloid plaques could vary between the rpAD and tAD. Differences in tau pathology between rpAD and tAD are also of interest. Additionally, mitochondrial dysfunction is a key early-stage change in tAD but has not yet been evaluated in rpAD.

objectiveTo deepen our understanding of the underlying pathophysiological processes specific to rpAD, we explore potential changes in tau pathology and mitochondrial dysfunction in rpAD compared to tAD.

methodsWe performed immunohistochemical and immunoblot analyses of tau, phosphorylated tau, and key regulators of mitochondrial dynamics and bioenergetics in postmortem human temporal cortex tissues obtained from patients diagnosed with tAD or rpAD, and tissues from age-matched normal subjects.

resultstAD was characterized by significant tau phosphorylation at the PHF1 epitope. Unexpectedly, rpAD showed milder PHF1 tau phosphorylation, similar to that of age-matched controls. Despite these differences in tau pathology, both tAD and rpAD exhibited a significant decrease in the key regulators of mitochondrial dynamics and bioenergetics compared to controls. However, the decline in mitochondrial dynamics regulators was more pronounced in rpAD.

conclusionsThese findings suggest divergent pathological processes between tAD and rpAD, specifically in terms of tau pathology and mitochondrial dynamic abnormalities, which underscore the necessity for different approaches to understand and potentially treat various AD subtypes.

Indexed as

Alzheimer DiseaseDisease ProgressionMitochondrial Dynamicstau ProteinsAgedAged, 80 and overFemaleHumansMaleMitochondriaNeurofibrillary TanglesPhosphorylationPlaque, AmyloidTemporal LobeMAPT protein, humantau ProteinsAlzheimer's diseaseamyloid plaquemitochondrial dynamicsmitochondrial dysfunctionneurofibrillary tanglesrapidly progressive Alzheimer's diseasetau

Identifiers

PMID39584307
PMCPMC12222553

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.